Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$27.60
-6.6%
$29.22
$23.15
$91.99
$11.43B1.838.23 million shs16.27 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$49.90
+1.1%
$47.54
$37.63
$51.88
$10.97B0.641.48 million shs1.43 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.95
-1.9%
$14.95
$12.26
$16.89
$11.87B0.291.54 million shs1.30 million shs
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$46.99
$46.89
$28.21
$62.00
$3.54B0.682.66 million shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
-6.63%-19.18%-8.85%-0.04%-76.85%
Qiagen N.V. stock logo
QGEN
Qiagen
+1.23%-3.66%+2.70%+15.64%+15.36%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-1.77%-4.88%-6.19%-0.36%-14.24%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
0.00%0.00%0.00%+1.64%+30.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
4.4709 of 5 stars
4.01.00.04.63.02.51.3
Qiagen N.V. stock logo
QGEN
Qiagen
3.2221 of 5 stars
1.22.01.74.52.11.71.3
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
1.9785 of 5 stars
2.52.01.70.01.40.01.9
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.1167.07% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.30
Hold$49.40-1.00% Downside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.00
Buy$16.9521.51% Upside
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
2.13
Hold$52.5711.88% Upside

Current Analyst Ratings Breakdown

Latest SWTX, MRNA, RDY, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$32.00
7/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$26.00 ➝ $25.00
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Hold
6/26/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $53.00
6/24/2025
Qiagen N.V. stock logo
QGEN
Qiagen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$55.00
6/5/2025
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.30N/AN/A$28.33 per share0.97
Qiagen N.V. stock logo
QGEN
Qiagen
$1.98B5.61$3.24 per share15.39$16.05 per share3.11
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B3.06$1.01 per share13.77$4.94 per share2.82
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
$191.59M18.48N/AN/A$6.47 per share7.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%N/A
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$0.40125.1120.282.514.68%14.61%8.80%8/5/2025 (Estimated)
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.6621.1417.015.6916.99%17.25%11.63%N/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%8/6/2025 (Estimated)

Latest SWTX, MRNA, RDY, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81N/AN/AN/A$73.39 millionN/A
8/5/2025Q2 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.60N/AN/AN/A$523.97 millionN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/23/2025Q1 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.18$0.20+$0.02$0.20$88.27 billion$988.82 million
5/9/2025Q4 24/25
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million
5/9/2025Q1 2025
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million
5/7/2025Q1 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.50%N/A62.50%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.50%N/A10.61%N/A
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/AN/AN/AN/AN/A

Latest SWTX, MRNA, RDY, and QGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.250.52%7/2/20257/3/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Qiagen N.V. stock logo
QGEN
Qiagen
0.40
3.37
2.83
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.01
1.89
1.36
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A
4.33
4.18

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
7.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,765222.29 million202.29 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.90 million818.20 millionOptionable
SpringWorks Therapeutics stock logo
SWTX
SpringWorks Therapeutics
23075.35 million69.45 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Moderna stock logo

Moderna NASDAQ:MRNA

$27.60 -1.96 (-6.63%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$27.72 +0.13 (+0.45%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Qiagen stock logo

Qiagen NYSE:QGEN

$49.90 +0.56 (+1.13%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$49.90 0.00 (0.00%)
As of 08/1/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$13.95 -0.27 (-1.90%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$13.94 -0.01 (-0.11%)
As of 08/1/2025 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

SpringWorks Therapeutics stock logo

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)
As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.